Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Neoplasms 3Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Uterine Cervical Neoplasms 1Sarcoma 1Kidney Neoplasms 1Endocrine Gland Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Doxorubicin 141Ifosfamide 85Radiotherapy 80Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 39Etoposide 39Docetaxel 39Vincristine 37Cisplatin 35Trabectedin 32Nivolumab 32Irinotecan 26Magnetic Resonance Spectroscopy 25Carboplatin 25Temozolomide 23Ipilimumab 22Bevacizumab 20Radiation 19Surgical Procedures, Operative 18Granulocyte Colony-Stimulating Factor 18Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17Biopsy 17eribulin 16anlotinib 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma × tariquidar × Clear all
NCT00011414 2019-07-16

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
29 enrolled
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡